NDUFAF6 Genotype

Most of what we call energy in the body comes from tiny power plants inside your cells. The gene tested here, NDUFAF6 (NADH dehydrogenase ubiquinone complex assembly factor 6), helps build a critical part of that machinery. Variants in this gene can quietly tilt your risk for severe mitochondrial disease earlier in life, kidney and lung problems in adulthood, and, based on early research, late-onset Alzheimer's disease decades later.

Knowing your NDUFAF6 status gives you a one-time genetic snapshot that standard blood panels cannot reveal. It can explain unexplained kidney or neurological symptoms in family members, add context to an Alzheimer's risk profile alongside better-established genes like APOE, and inform conversations about how to monitor brain and kidney health over the coming decades.

What This Gene Actually Does

Your cells generate energy through a series of large protein assemblies inside mitochondria (the power plants inside every cell). The first and largest of these assemblies is called complex I. NDUFAF6 does not become part of the final structure itself, but it acts as a builder, helping fit the pieces together correctly. When this gene works normally, complex I gets assembled, energy production runs smoothly, and tissues with high energy demands, like the brain and kidney, function as expected.

When NDUFAF6 carries certain variants, the builder cannot do its job. Complex I assembly stumbles, energy output drops, and the tissues most dependent on continuous energy supply are the first to feel it. This is why diseases linked to NDUFAF6 cluster around the brain, kidneys, and lungs.

Late-Onset Alzheimer's Disease Risk

Early research has linked common variants in or near NDUFAF6 to a higher risk of late-onset Alzheimer's disease. A large European meta-analysis (the GR@ACE project) flagged rs10098778 as a novel signal, and a separate study in older adults in rural China highlighted rs6982393. The evidence base is still modest compared with well-established Alzheimer's risk loci like APOE, and the level of cross-population replication is limited.

In a cross-sectional study of 5,096 Chinese rural older adults, people carrying two copies of the T variant at rs6982393 were roughly 60% more likely to have Alzheimer's disease compared with people carrying one or zero T copies (odds ratio about 1.61). The link was stronger in the 60 to 69 age group, and the risk was higher still when the rs6982393 TT genotype was combined with the APOE epsilon 4 risk variant. Interestingly, in that specific cohort APOE epsilon 4 on its own was not significantly associated with Alzheimer's risk, which is a reminder that genetic signals can behave differently across populations. The same study found no link between this NDUFAF6 variant and mild cognitive impairment, suggesting the variant may relate to full Alzheimer's specifically rather than early memory complaints.

What this means for you: if you carry a risk variant at NDUFAF6, your absolute lifetime risk of Alzheimer's may be shifted upward, but the variant alone does not determine your fate, and the evidence is still preliminary. Combined with APOE status, family history, and cardiovascular risk factors, it adds one more piece of context for thinking about cognitive health and modifiable risks like blood pressure, blood sugar, and inflammation.

Leigh Syndrome and Severe Mitochondrial Disease

When a person inherits two damaged copies of NDUFAF6 (one from each parent), the result can be Leigh syndrome, a severe neurodegenerative condition that usually appears in infancy or early childhood. The disease comes from a profound shortage of working complex I, which starves the brain and brainstem of energy. In a Japanese registry of 166 children with genetically confirmed Leigh syndrome, those whose disease traced back to NDUFAF6 tended to have relatively milder symptoms and better survival than children with several other genetic subtypes.

For most adults learning their NDUFAF6 status, the implication is not that you have Leigh syndrome, but that you could be a carrier. If you carry one damaged copy and your reproductive partner carries one as well, your biological children would have a one-in-four chance of inheriting two damaged copies. This is the conversation that often matters most for adults of reproductive age.

Acadian Fanconi Syndrome, Kidney Disease, and Lung Fibrosis

A specific NDUFAF6 variant, the intronic change rs575462405 (also written c.298-768 T>C), is the cause of Acadian Fanconi syndrome. The variant disrupts how the gene is spliced, eliminating a version of NDUFAF6 that is specifically needed in kidney and lung tissue. The downstream consequences include a leaky proximal tubule (the part of the kidney that reabsorbs nutrients), progressive chronic kidney disease, and pulmonary fibrosis (lung scarring).

This variant has been described in the Acadian founder population of Nova Scotia, Canada, which is why ancestry context matters when interpreting your result. If you carry two copies of this specific variant, the diagnosis is established and ongoing kidney and lung monitoring become important. If you carry one copy, your own risk is generally low, but the carrier status is relevant for family planning.

Cerebral Small Vessel Disease

A small study of 50 people with cerebral small vessel disease identified a heterozygous NDUFAF6 variant, p.Ala92Val, as a possible contributor in one case. The link is not yet established. This finding sits at the very preliminary edge of the evidence and should be treated as a research signal rather than a confirmed association.

Reconciling the Tier of This Test

NDUFAF6 sits in an unusual position. On one end of the spectrum, certain variants are clearly disease-causing, with decades of evidence linking biallelic damaging mutations to Leigh syndrome and the Acadian splicing variant to a specific kidney-lung phenotype. On the other end, common variants like rs6982393 may nudge late-life Alzheimer's risk in ways that appear real but remain preliminary and based on a limited evidence base. The same gene can therefore tell you something nearly certain about one risk and something exploratory about another. Read your result with that asymmetry in mind.

A One-Time Test, A Lifetime of Decisions

Your NDUFAF6 genotype is set at conception and does not change. There is no value in retesting the gene itself unless you have reason to question the accuracy of the original call (for example, a result that contradicts strong clinical evidence, or a direct-to-consumer chip result that warrants confirmation by clinical-grade sequencing). The ongoing value of this test comes from integrating the result into other decisions over years.

If you carry a higher-risk variant, the testing that is worth tracking more carefully is not this gene, but the downstream phenotype markers. No professional society currently recommends altering screening schedules based on NDUFAF6 genotype alone, so the decisions below are individual choices to discuss with your clinician rather than guideline-endorsed protocols. For Alzheimer's risk, that conversation might cover when to establish a baseline of cognitive function, how closely to track vascular risk factors, and whether plasma biomarkers like amyloid beta and phosphorylated tau make sense as those tests mature. For kidney involvement, especially in people with Acadian ancestry or known carrier status, that conversation often includes a basic metabolic panel, cystatin C-based eGFR, and a urine albumin-to-creatinine ratio. For lung involvement in the same population, periodic pulmonary function testing makes sense if symptoms develop.

When Results Can Be Misleading

• Variant panel coverage: the assay only detects the specific NDUFAF6 variants it is designed to detect. A negative result does not rule out rare or novel variants in the same gene that the panel does not cover.
• Ancestry context: some risk variants are common in one population and rare in another. The Acadian Fanconi variant is concentrated in the Acadian founder population of Nova Scotia, while the Alzheimer's risk variants have been studied mainly in European populations and in Chinese rural older adults. The clinical meaning of your result depends on your background.
• Variants of uncertain significance: if the report flags a variant whose effect is unknown, that does not mean you are at risk. It means the science has not yet caught up to that particular change.
• Clinical-grade versus direct-to-consumer: a 23andMe-style report covering an NDUFAF6 locus is not equivalent to a clinical-grade sequencing result. Confirm important findings with a clinical laboratory before acting on them.

Decision Pathway for an Out-of-Pattern Result

If your result shows a known disease-causing variant or a strong risk variant, the next step is not to retest the gene. It is to expand the workup in directions the variant points to. For an Alzheimer's-associated genotype, that may mean pairing this result with APOE testing, a lipid panel, fasting glucose and HbA1c, blood pressure tracking, and a baseline of cognitive screening to compare against in future years. For the Acadian splicing variant, that means kidney function testing (creatinine, cystatin C, eGFR, urine albumin) and pulmonary function testing if any respiratory symptoms appear.

A genetic counselor or a clinical geneticist should be involved if the result includes a clearly pathogenic variant, especially before you discuss results with biological family members or make reproductive decisions. For uncertain or research-grade findings (such as a heterozygous variant linked only to a single small study), watchful observation paired with ongoing tracking of relevant organ-system labs is usually more useful than further genetic workup.